Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corp (ENOV) operates in the medical technology sector, manufacturing orthopedic implants, bracing products, and rehabilitation equipment. The company's news flow reflects its position as a pure-play orthopedic device manufacturer following its corporate transformation from diversified industrial operations.
News coverage for Enovis typically centers on quarterly and annual financial results, providing insights into performance across its Prevention & Recovery and Reconstructive business segments. Earnings announcements reveal trends in surgical implant demand and rehabilitation equipment sales, key metrics for evaluating the company's market position in orthopedic care.
Product development and regulatory milestones represent another significant category of Enovis news. Medical device companies require FDA clearances and international approvals for new products, making regulatory announcements important for understanding the company's pipeline progression. Surgeon partnerships and clinical study results may also generate coverage relevant to product positioning.
Corporate development activity, including business acquisitions, divestitures, and strategic portfolio adjustments, frequently appears in Enovis news. The company's focused medical technology strategy may lead to announcements about expanding or refining its orthopedic product offerings. Leadership transitions and executive appointments also generate coverage given their impact on company direction.
Investor conference participation and analyst day presentations offer additional context on company strategy and market outlook. These events provide management perspectives on orthopedic market dynamics, competitive positioning, and growth initiatives that may not appear in standard earnings releases.
Bookmark this page to follow Enovis Corp news and track developments across the orthopedic medical device industry.
Enovis (NYSE: ENOV) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference, with a presentation on Monday, January 12, 2026 at 4:30 p.m. PST (7:30 p.m. EST).
A live audio webcast, accompanying presentation slides, and a replay will be available on the company website under Events and Presentations.
Enovis (NYSE: ENOV) appointed Oliver Engert as Chief Administrative Officer, effective January 5, 2026.
In this newly created role, Engert will lead strategy development, drive organizational efficiency, and enhance operational excellence to support the company’s next phase of profitable, capital-efficient growth. Engert joins from McKinsey & Company after 30 years there, most recently as Senior Partner Emeritus, Special Advisor, and will be primarily based in Lewisville, Texas.
Enovis (NYSE: ENOV) reported third-quarter 2025 results for the period ended October 3, 2025, with net sales of $549 million, up 9% reported and 7% organic year‑over‑year. Recon sales rose 12% reported (9% organic); P&R sales grew 6% reported (4% organic). The company reported a GAAP net loss of $571 million driven by a $548 million non‑cash goodwill impairment, and adjusted EBITDA was $95 million (17.3% margin) with adjusted EPS of $0.75. Enovis completed the October divestiture of its Diabetic Footcare business for up to $60 million and raised full‑year 2025 adjusted EBITDA and adjusted EPS guidance, with revenue guidance narrowed to $2.24–2.27 billion.
Enovis (NYSE: ENOV) announced it will release Third Quarter 2025 financial results and host a conference call and live webcast on Thursday, November 6, 2025 at 8:30 a.m. ET, with an earnings press release issued earlier that morning.
A presentation and live webcast will be available on the Enovis Investors website. Executives will also participate in investor conferences: a UBS Global Healthcare fireside chat on Monday, November 9 at 2:45 p.m. ET and a Jefferies London Healthcare fireside chat on Tuesday, November 18 at 3:30 p.m. GMT (10:30 a.m. ET). Live audio webcasts and replays will be posted under Investors > Events and Presentations.
Enovis (NYSE: ENOV) completed the sale of its Dr. Comfort footcare diabetic shoe business to Promus Equity Partners for up to $60 million in cash, comprising an $45 million upfront payment and up to $15 million in milestone payments.
The company said the divestiture sharpens focus on its Prevention & Recovery franchise, aims to expand margins, enhance profitability, and accelerate debt reduction. Enovis will discuss strategic details on its Q3 results call on Nov 6, 2025 at 8:30 am ET. Promus is a multi-family asset manager with approximately $2.7 billion under management. Citizens Capital Markets & Advisory and Tucker Ellis LLP advised Enovis.
Enovis Corporation (NYSE:ENOV), a medical technology growth company, has announced a schedule change for its presentation at the Baird 2025 Global Healthcare Conference. The company will now present on Wednesday, September 10th, 2025 at 2:35 p.m. ET. Investors can access both the live audio webcast and replay through the Events and Presentations section under the Investors tab on Enovis' website.
Enovis Corporation (NYSE: ENOV), a medical technology growth company, has announced its upcoming participation in three major investor conferences:
- Canaccord Genuity 45th Annual Growth Conference on August 13th at 8:30 a.m. ET
- Wells Fargo Healthcare Conference on September 3rd at 2:15 p.m. ET
- Baird 2025 Global Healthcare Conference on September 10th at 3:10 p.m. ET
Live audio webcasts and replays will be accessible through the Investors section of the company's website under Events and Presentations.
Enovis (NYSE:ENOV) reported strong Q2 2025 financial results with net sales of $565 million, representing a 7% reported growth and 5% organic growth year-over-year. The company's Reconstructive segment grew 11% on a reported basis, while Prevention & Recovery (P&R) increased 5%.
Despite positive sales growth, Enovis recorded a net loss of $37 million (6.5% of sales) and adjusted EBITDA of $97 million (17.2% of sales). The company updated its 2025 guidance, raising revenue expectations to $2.245-2.275 billion and adjusted EPS guidance to $3.05-3.20.
Enovis Corporation (NYSE: ENOV), a medical technology growth company, will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. ET. The company will release its earnings report earlier that morning.
Investors can access the live webcast through Enovis' website investor section, and those wishing to participate in the call can dial (833) 685-0901. A presentation and replay of the call will be available on the company's website following the event.
FAQ
What is the current stock price of Enovis (ENOV)?
What is the market cap of Enovis (ENOV)?
